Stamford – November 10, 2026 -- Kolmena's agentic AI platform has cut time spent on regulatory research by 85% at Celnova Pharma, the company said as it launched the multi-agent system with access by invitation only.
Platform routes tasks across multiple AI models to manage cost and performance
Kolmena groups specialized AI agents into coordinated workforces that share context and work toward a common objective. Its Kolmena Smart Prompt Routing (KSPR) assigns different AI models to different tasks within a workflow. Users can tune performance and cost without depending on a single AI provider.
The platform offers more than 1,600 integrations, persistent memory, governance and observability. It launches with an Agent Builder, a Swarm Builder and an implementation partner program for agencies, consultancies and AI specialists.
Celnova Pharma automates FDA and EMA approval monitoring
Kolmena powers a regulatory intelligence workflow for Celnova Pharma. The workflow monitors FDA and EMA drug approvals, identifies molecules that match the company's therapeutic and commercial priorities, and organizes potential opportunities for business development teams.
The next phase will identify prospective licensing partners earlier in the drug development cycle, evaluate market opportunities and coordinate commercial follow-ups.
Enterprise controls target organizations, MAYA targets individuals
Organizations get an AI coordination layer with enterprise controls and the option to build specialized workforces. Individuals get a personal AI workforce through MAYA, the company's AI companion, with free entry and usage-based plans.
Agents exchange context, instructions and results among themselves, so users do not have to manage every individual prompt. Access is currently by invitation only. Kolmena is a U.S.-based company with an office in Stamford, Connecticut, and a team distributed across the United States, Europe and Latin America.